Dr. Joshua Lukenbill
Claim this profileMedical Oncology and Hematology Associates-Des Moines
Expert in Cancer
Expert in Breast Cancer
140 reported clinical trials
215 drugs studied
About Joshua Lukenbill
Education:
- Earned dual BS degrees in biochemistry and psychology from The University of Iowa.
- Attended medical school at A.T. Still University, Kirksville, MO.
- Completed an Internal Medicine residency and Hematology/Oncology fellowship at The Cleveland Clinic.
Experience:
- Board Certified in Oncology, Hematology, and Internal Medicine.
- Joined Mission in 2017 and is currently practicing in Des Moines, IA.
- Holds roles in research and education with affiliations to Iowa Methodist Medical Center, University of Iowa, and Des Moines University.
- Active member of the American Society of Hematology and American Society of Clinical Oncology.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
KRAS positive
2Breast Cancer
Global LeaderStage IV
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Joshua Lukenbill is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
More about Joshua Lukenbill
Clinical Trial Related2 years of experience running clinical trials · Led 140 trials as a Principal Investigator · 69 Active Clinical TrialsTreatments Joshua Lukenbill has experience with
- Nivolumab
- Cisplatin
- Radiation Therapy
- Fluorouracil
- Atezolizumab
- Paclitaxel
Breakdown of trials Joshua Lukenbill has run
Cancer
Breast Cancer
Lung Cancer
Thyroid Cancer
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Joshua Lukenbill specialize in?
Is Joshua Lukenbill currently recruiting for clinical trials?
Are there any treatments that Joshua Lukenbill has studied deeply?
What is the best way to schedule an appointment with Joshua Lukenbill?
What is the office address of Joshua Lukenbill?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.